E
Sigyn Therapeutics, Inc.
SIGY
$4.10
-$0.0099-0.24%
E
Sell
11/23/2022Downgrade
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D- on 11/23/2022 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 32.81% from -$394.7 to -$524.2, and EBIT declined 0.15% from -$532.8 to -$533.6.
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D- on 11/23/2022 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 32.81% from -$394.7 to -$524.2, and EBIT declined 0.15% from -$532.8 to -$533.6.
D
Sell
11/4/2022Upgraded
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E+ on 11/4/2022 due to an increase in the volatility index and total return index.
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E+ on 11/4/2022 due to an increase in the volatility index and total return index.
E
Sell
10/20/2022Downgrade
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D- on 10/20/2022 due to a decline in the volatility index.
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D- on 10/20/2022 due to a decline in the volatility index.
D
Sell
10/5/2022Upgraded
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E+ on 10/5/2022 due to an increase in the volatility index.
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E+ on 10/5/2022 due to an increase in the volatility index.
E
Sell
9/20/2022Downgrade
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D- on 9/20/2022 due to a decline in the volatility index, total return index and valuation index.
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D- on 9/20/2022 due to a decline in the volatility index, total return index and valuation index.
D
Sell
8/31/2022Upgraded
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E+ on 8/31/2022 due to an increase in the volatility index, total return index and valuation index.
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E+ on 8/31/2022 due to an increase in the volatility index, total return index and valuation index.
E
Sell
8/16/2022Downgrade
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D on 8/16/2022 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 0.09 to 0.01, and debt to equity increased from -1.03 to -0.84.
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D on 8/16/2022 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 0.09 to 0.01, and debt to equity increased from -1.03 to -0.84.
D
Sell
8/10/2022Upgraded
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D from D- on 8/10/2022 due to an increase in the volatility index and valuation index.
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D from D- on 8/10/2022 due to an increase in the volatility index and valuation index.
D
Sell
7/8/2022Downgrade
Sigyn Therapeutics, Inc. (SIGY) was downgraded to D- from D on 7/8/2022 due to a decline in the volatility index.
Sigyn Therapeutics, Inc. (SIGY) was downgraded to D- from D on 7/8/2022 due to a decline in the volatility index.
D
Sell
6/22/2022Upgraded
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D from D- on 6/22/2022 due to a noticeable increase in the growth index, volatility index and solvency index. EBIT increased 45.94% from -$1.13M to -$609.2, earnings per share increased from -$0.033 to -$0.02, and operating cash flow increased 16.89% from -$553 to -$459.6.
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D from D- on 6/22/2022 due to a noticeable increase in the growth index, volatility index and solvency index. EBIT increased 45.94% from -$1.13M to -$609.2, earnings per share increased from -$0.033 to -$0.02, and operating cash flow increased 16.89% from -$553 to -$459.6.
D
Sell
5/5/2022Upgraded
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D- on 4/20/2022 due to a significant decline in the solvency index, volatility index and growth index. EBIT declined 96.55% from -$573.4 to -$1.13M, earnings per share declined from -$0.02 to -$0.033, and the quick ratio declined from 0.61 to 0.46.
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D- on 4/20/2022 due to a significant decline in the solvency index, volatility index and growth index. EBIT declined 96.55% from -$573.4 to -$1.13M, earnings per share declined from -$0.02 to -$0.033, and the quick ratio declined from 0.61 to 0.46.
D
Sell
11/15/2021Upgraded
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E+ on 11/15/2021 due to an increase in the growth index.
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E+ on 11/15/2021 due to an increase in the growth index.
E
Sell
8/18/2021Downgrade
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D- on 8/18/2021 due to a noticeable decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.0131 to -$0.02, operating cash flow declined 48.36% from -$274.4 to -$407.1, and EBIT declined 9.87% from -$402.1 to -$441.8.
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from D- on 8/18/2021 due to a noticeable decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.0131 to -$0.02, operating cash flow declined 48.36% from -$274.4 to -$407.1, and EBIT declined 9.87% from -$402.1 to -$441.8.
D
Sell
7/1/2021Upgraded
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E on 07/01/2021.
Sigyn Therapeutics, Inc. (SIGY) was upgraded to D- from E on 07/01/2021.
E
Sell
6/3/2021Downgrade
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E from E+ on 6/3/2021 due to a decline in the volatility index and total return index.
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E from E+ on 6/3/2021 due to a decline in the volatility index and total return index.
E
Sell
5/21/2021None
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from U on 05/21/2021.
Sigyn Therapeutics, Inc. (SIGY) was downgraded to E+ from U on 05/21/2021.
OTC PK
03/04/2025 1:41PM Eastern
Quotes delayed
